Sleep disorders are common problems and have been reported in 10% to 40% of the general population ([@R1]). These problems can affect quality of life, physical and social functioning and can also cause chronic fatigue ([@R1]). It seems that HIV (human immunodeficiency virus) infected individuals are more vulnerable to sleep disturbances ([@R2]). Based on Pittsburg Sleep Quality Index, it has been reported that 73 % to 100% of HIV positive patients suffer from various degrees of sleep problems ([@R3]-[@R4]). Normal sleep architecture can be changed ([@R1]-[@R2]), and slow wave sleep may be increased significantly in HIV positive individuals ([@R5]-[@R7]). Greater sleep onset latency, early morning awakening, more frequent awakenings during the night, and reduced sleep efficiency have been reported in this population ([@R8]-[@R11]). Anxiety and depression are psychological factors that affect sleep quality ([@R1], [@R12]-[@R13]). Sleep disturbance is a common symptom of depression ([@R13]). Patients with anxiety disorders have delayed sleep onset and reduced total sleep time ([@R12]). HIV positive patients with higher levels of depression or anxiety showed more sleep disturbances than HIV positive individuals without depression and anxiety symptoms ([@R8]). Physical symptoms such as pain, abdominal cramping, diarrhea, incontinence, itching, burning, fever, night sweats, cough and dyspnea can also cause sleep disturbances in HIV positive patients ([@R8]). Some studies have suggested an inverse correlation between immune system and sleep quality in HIV positive patients ([@R14]-[@R15]), but others did not show this relationship ([@R5], [@R16]-[@R17]). The frequency of sleep disturbances was evaluated in different populations such as general population (35.2%) ([@R18]), renal transplant (62%) ([@R19]), dialysis (73.8%) ([@R20]), multiple sclerosis (87.2%) ([@R21]) and cancer patients (71.7%) ([@R18]). Sleep quality and its correlated factors have not been evaluated in the Iranian HIV positive individuals. The aim of this study was to evaluate the sleep quality and its related psychological and physiological factors in the Iranian HIV positive patients who were candidates for initiation of antiretroviral therapy.

Material and Methods {#S1}
====================

This cross-sectional study was conducted in the HIV Clinic of Imam Khomeini Hospital Complex in Tehran, Iran during a one year period. Fifty nine (42 males and 17 females), 18 to 55 year old HIV positive patients were included in this survey. The stages of HIV infection were determined according to 1993 revised classification of centers for disease control and prevention (CDC) definition. The stages A, B and C are based on patients' clinical condition related to HIV infection. The stages 1, 2 and 3 are based on patients' CD4 cells count. The CD4 cell counts for stages 2 and 3 are 200/μl to 499/μl and below 200/μl, respectively ([@R22]). All the participants had CD4 cell counts of less than 350/μl and were candidates for initiation of antiretroviral therapy. The patients' demographic and laboratory data were collected. Pittsburg Sleep Quality Index (PSQI), the validated Persian versions of Hamilton Depression Rating Scale (HDRS), Hamilton Anxiety Rating Scale (HARS) ([@R23]) and Somatization Subscale of Symptom Checklist 90 (SCL-90) ([@R24], [@R25]) were used to assess the patients' sleep quality, depression, anxiety and physiological factors, respectively. It should be explained that PSQI is a self measured, 7-component questionnaire including subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medications and daytime dysfunction during the last month. The validated Persian version of PSQI (Cronbach's alpha= 0.77) was utilized in the present study ([@R26]); PSQI of greater than 5 was considered as sleep disturbance ([@R11]). An expert interviewer completed the HDRS and HARS questionnaires. The HDRS is a 17-item scale, and it is categorized from 0 to 4 ([@R27]). The HARS evaluates 14 anxiety related parameters, with scores of 0 to 4 ([@R28]). Somatization dimension of SCL-90 represents physical morbidity. This self- reported questionnaire includes 12 items. This subscale represents distress in different systems of the body such as cardiovascular, gastrointestinal, respiratory, autonomic systems and is rated from 0 (none) to 4 (extreme) ([@R29]). SPSS software version 12 was used for data analysis. Normal distribution of the variables was assessed according to Kolmograph-Smirnov test. The Pearson correlation coefficient was used to analyze the correlation between PSQI and other quantitative variables. The patients were assigned into two groups: patients with normal sleep and patients with sleep disturbance (PSQI score \> 5). The Chi-square test was used to determine the relationship between these two groups and the stages of HIV infection. P value of less than 0.05 was considered as statistically significant.

Result {#S2}
======

Fifty nine HIV positive patients (42 males and 17 females) with the mean ± SD age of 36.9 ± 9.8 were included in the study. The patients' demographic data were summarized in [Table 1](#T1){ref-type="table"}. In this study, 42.4% of the patients had a high-school diploma, 55.9% were married and 52.5% were self-employed. The most common routes of HIV transmission were sexual contacts (35.6 %) and injection drug use (33.9 %). Oral candidiasis (10.2 %) and chronic hepatitis C (23.7%) were the most common opportunistic infection and concomitant disease in the patients.

The patients' mean ± SD of PSQI, HDRS, HARS and Somatization Subscale of SCL-90 scores were 5.88 ± 4.22, 12.58 ± 7.18, 8.58 ± 5.78 and 11.29 ± 7.45, respectively. The classification of these scores is demonstrated in [Table 2](#T2){ref-type="table"}.

Based on the sleep quality assessment, 47.5 % of the patients had PSQI \> 5 that was defined as sleep disturbances. A significant correlation was found between sleep quality and HDRS (r = 0.531, p = 0.0001), HARS (r = 0.627, p= 0.0001) and Somatization Subscale of SCL-90 (r = 0.36, p = 0.05) ([Table 3](#T3){ref-type="table"}). The frequency of PSQI \> 5 of the patients in different stages of HIV infection are displayed in [Table 4](#T4){ref-type="table"}. The correlation between the patients' HIV infection stages and PSQI scores was significant , (X2 (1) = 5.732, p = 0.017). There was not any significant correlation between the patients' laboratory data and their sleep quality except neutrophil percentage (r = 0. 309, p = 0.023).

Discussion {#S3}
==========

Although sleep disorders are common problems in the general population, the prevalence of sleep disorders is more common in the HIV positive population than the general population, and it can affect the quality of life of these patients ([@R1]). The correlation between the severity of HIV infection and its progression to advanced stages of this disease has been reported in several studies ([@R8], [@R14]-[@R15]). We detected sleep disturbances in 47.5 % of the Iranian HIV positive individuals who were candidates for antiretroviral therapy. Sleep disorders have been reported in 63% to 100% of other HIV positive populations ([@R2], [@R8], [@R11]).

Wibbeler et al. Reported that 63.9 % of the HIV positive patients could be classified as poor sleepers based on the PSQI score ([@R11]). In another study, Robbins et al. found that all their HIV infected participants suffered from sleep disturbance ([@R8]).

In our patients, the prevalence of sleep disorders was similar to 10% to 40% of the Iranian general population and to other countries ([@R2], [@R19], [@R30]).

Sleep disorders were reported in 32.1 % of the Austrian general population ([@R31]). In a random sample study of an Iranian urban population, sleep disturbances were detected in 37% of the participants ([@R30]). Nearly equal prevalence of sleep disturbances in our HIV positive individuals and the general population may be attributed to our inclusion criteria of the study. We evaluated HIV positive out-patients with CD4 count of lower than 350/μl. These patients did not receive antiretroviral therapy and did not complain about serious concomitant diseases or opportunistic infections. Predisposing factors for sleep disturbances in this population have been reported as antiretroviral, complications of concomitant diseases and opportunistic infections including general pain, abdominal cramping, diarrhea, incontinence, itching, burning, fever, night sweats, cough and dyspnea ([@R8]). In white et al. study, no difference was observed between HIV positive patients with CD4 counts of less than 400 and seronegative controls in sleep disturbance frequency ([@R7]).

A significant correlation was found between the stages of HIV infection and sleep disturbances in the present study. In previous studies, it was reported that the quality of sleep will be worsen along with disease progression in HIV positive individuals ([@R8], [@R14]-[@R15]). Darko et al. reported that sleep disturbances was related to CDC stages of HIV infection ([@R15]). The risk of opportunistic infections and an indication for antibiotic prophylaxis will increase with HIV infection progression in this population. Opportunistic infections can produce various symptoms including pain, fever, night sweet, pain, cough and dyspnea that can disturb patients' sleep ([@R8]).

Our findings showed that both psychological and physiological factors can affect sleep quality. We found a direct correlation between sleep disturbance and depression, anxiety and physical morbidity as measured by HDRS, HARS and Somatization Subscale of SCL- 90. These findings are in line with the results of other studies ([@R2], [@R8], [@R11]). Depression is the most important factor that affects sleep quality ([@R11]); physiological factors such as pain and psychological factors such as psychological stressors in HIV positive patients can also affect their sleep quality ([@R1]). We used the HDRS and HARS to assess depression and anxiety, and we found they are correlated with sleep quality ([@R8]).

Depression and anxiety are frequent depression and anxiety status in our patients. These questionnaires have been used to evaluate these mental disorders in HIV positive patients in another study ([@R16]). HIV positive individuals with anxiety have problems in falling asleep, decreased slow wave sleep and more non REM sleep ([@R2], [@R8]). In this study, physical morbidity in HIV infected patients was assessed based on Somatization Subscale of SCL- 90. This questionnaire has been used in HIV positive population in another study in Iran ([@R24]). Physical morbidities including pain, abdominal cramping, diarrhea, incontinence, itching, burning, fever, night sweats, cough and dyspnea are common problems in HIV infected patients. These morbidities can cause problems in falling asleep and may diminish sleep efficiency ([@R8]). Also, pain may cause non-restorative sleep in HIV positive individuals ([@R1]).

Limitations {#S4}
===========

The limitations of this study were the small sample size and the absence of control group. Sleep disturbances and predisposing factors should be evaluated in a prospective and well controlled study with sufficient sample size.

We suggest that treatment of depression, anxiety and physical morbidity can improve sleep quality in HIV positive patients.

Conclusion {#S5}
==========

This study showed that human immunodeficiency virus positive individuals suffer from sleep disorders at least as same as the general population, and that psychological variables including depression and anxiety and physiological variables including physical morbidities in different systems of the body lead to sleep disturbance in this population.

This study was a part of Dr Dabaghzadeh's thesis toward graduation from post-doctoral residency in clinical pharmacy and was supported by Faculty of Pharmacy, Tehran University of Medical Sciences (grant number: 89-04-33-11884).

###### 

Demographic data of the patients

  Characteristics                                                  Frequency (percent) or Mean± SD
  -------------------------------------------- ------------------- ---------------------------------
  **Sex**                                      Male                42 (71.2 %)
  Female                                       17 (28.8 %)         
  **Age**                                      36.9 ± 9.8          
  **Weight**                                   65.9 ± 12.7         
  **Period between diagnosis and treatment**   19.14 ± 25.23       
  **CD~4~ count**                              157.91 ±117.23      
  **Education**                                Illiterate          4 (6.8 %)
  Elementary                                   9 (15.3 %)          
  Guidance school                              13 (22.0 %)         
  High school                                  25 (42.4 %)         
  More than Diploma                            8 (13.6%)           
  **Transmission**                             IV drug injection   20 (33.9 %)
  Sex                                          21 (35.6 %)         
  Needle                                       1 (1.7 %)           
  IV drug injection and sex                    11 (18.6 %)         
  Unknown                                      4 (6.8 %)           
  Blood                                        2 (3.4 %)           
  **Job**                                      Self-employed       31 (52.5 %)
  House-hold                                   9 (15.3 %)          
  Employee                                     4 (6.8 %)           
  Student                                      3 (5.1 %)           
  Taxi driver                                  4 (6.8 %)           
  Unemployed                                   6 (10.2 %)          
  Engineer                                     1 (1.7 %)           
  Medical staff                                1 (1.7 %)           
  **Opportunistic Infection**                  TB                  1 (1.7 %)
  CMV                                          2 (3.4 %)           
  Candidiasis                                  6 (10.2 %)          
  None                                         47 (79.7 %)         
  Zoster                                       2 (3.4 %)           
  TB and Candidiasis                           1 (1.7 %)           
  **Concomitant disease**                      Diabetes            1 (1.7 %)
  Depression                                   1 (1.7 %)           
  HBV                                          2 (3.4 %)           
  HCV                                          11 (18.6 %)         
  GI disease                                   3 (5.1 %)           
  None                                         38 (64.4 %)         
  HBV and HCV                                  3 (5.1 %)           
  **State of marriage**                        Single              19 (32.2 %)
  Married                                      33 (55.9 %)         
  Divorced                                     7 (11.9 %)          

The patients' demographic data including age, sex, duration of HIV infection, CD4 count, HIV transmission rout, education, job and baseline diseases and concomitant infections.

IV: Intravenous, TB: Tuberculosis, CMV: Cytomegalovirus, HCV: Hepatitis C virus, HBV: Hepatitis B virus, GI: Gastrointestinal, SD: Standard deviation

###### 

Classification of the patients' depression, anxiety and sleep quality status

  Parameter                        Score                       Frequency (%)   Mean ± SD
  -------------------------------- --------------------------- --------------- ---------------
  **Depression**                   Normal (0-7)                12 (20.3 %)     12.58+/- 7.18
  Mild Depression (8-13)           22 (37.3 %)                                 
  Moderate Depression (14-18)      11 (18.6 %)                                 
  Severe Depression (19-22)        8 (13.6 %)                                  
  Very Severe Depression (≥ 23)    6 (10.2 %)                                  
  **Anxiety**                      Normal (0-13)               46 (78 %)       8.58+/- 5.78
  Mild Anxiety (14-17)             11 (18.6 %)                                 
  Moderate Anxiety (18-24)         1 (1.7 %)                                   
  Severe Anxiety (25-30)           1 (1.7 %)                                   
  **Sleep quality**                Patient with normal sleep   31 (52.5 %)     5.88+/- 4.22
  Patient with sleep disturbance   28 (47.5 %)                                 

The patients' depression, anxiety and sleep quality were assessed and categorized based on the Hamilton Depression Rating Scale (HDRS), Hamilton Anxiety Rating Scale (HARS) and Pittsburg Sleep Quality Index (PSQI), respectively

###### 

Correlation between sleep quality and neuropsychiatric scales

  Scales                           Correlation coefficient   p value
  -------------------------------- ------------------------- ---------
  HDRS                             0.531                     0.0001
  HARS                             0.627                     0.0001
  Somatization subscale of SCL90   0.36                      0.05

HDRS: Hamilton Depression Rating Scale, HARS: Hamilton Anxiety Rating Scale, SCL90: Symptom Checklist 90

###### 

Data of stages of HIV infection and patients with and without sleep disturbance

  Stage of HIV infection   Patients with normal sleep, frequency (%)   Patients with disturbed sleep, frequency (%)   P value
  ------------------------ ------------------------------------------- ---------------------------------------------- ---------
   **2**                   16 (27.1 %)                                 6 (10.2 %)                                     0.017
   **3**                   31 (25.4 %)                                 22 (37.3 %)                                    
   **A**                   25 (42.4 %)                                 22 (37.2 %)                                    0.981
   **B**                   4 (6.8 %)                                   4 (6.8 %)                                      
   **C**                   2 (3.4 %)                                   2 (3.4 %)                                      

Stage of HIV infection was determined according to 1993 revised classification of centers for disease control and prevention (CDC) definition. The Chi-square test was used to determine the relationship between these two groups and stages of HIV infection
